NASDAQ:DMAC
DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. reported net income of −$32.8M in fiscal 2025. Free cash flow was −$29.1M.Summary generated from DiaMedica Therapeutics Inc.'s SEC filings. Latest annual report filed Mar 30, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−67.7%
Debt / equityn/a
Free cash flow−$29.1M
FCF marginn/a
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −14 | −14 | −21 | −27 | −34 |
| Net income | −14 | −14 | −19 | −24 | −33 |
| Free cash flow | −12 | −12 | −19 | −22 | −29 |
Recent filings
- 4Insider transaction report
Aug 12, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 10, 2026 - 8-KResults of operations and financial condition
Aug 10, 2026 - 4Insider transaction report
Jun 3, 2026 - 8-KResults of a shareholder vote
May 21, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 6, 2026 - 8-KResults of operations and financial condition
May 6, 2026 - DEF 14AProxy statement
Apr 1, 2026